These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 38279263)

  • 1. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
    Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage checkpoint kinases in cancer.
    Smith HL; Southgate H; Tweddle DA; Curtin NJ
    Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging strategies for cancer therapy by ATR inhibitors.
    Yano K; Shiotani B
    Cancer Sci; 2023 Jul; 114(7):2709-2721. PubMed ID: 37189251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
    Gupta N; Huang TT; Horibata S; Lee JM
    Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting replication stress in cancer therapy.
    da Costa AABA; Chowdhury D; Shapiro GI; D'Andrea AD; Konstantinopoulos PA
    Nat Rev Drug Discov; 2023 Jan; 22(1):38-58. PubMed ID: 36202931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
    Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
    PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Smith HL; Willmore E; Prendergast L; Curtin NJ
    Br J Cancer; 2024 Sep; 131(5):905-917. PubMed ID: 38965423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.
    Liu S; Opiyo SO; Manthey K; Glanzer JG; Ashley AK; Amerin C; Troksa K; Shrivastav M; Nickoloff JA; Oakley GG
    Nucleic Acids Res; 2012 Nov; 40(21):10780-94. PubMed ID: 22977173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of ATR-CHK1 signaling by ubiquitination of CLASPIN.
    Zhu X; Zheng XY; Gong P; Xu X
    Biochem Soc Trans; 2022 Oct; 50(5):1471-1480. PubMed ID: 36196914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
    Ngoi NY; Sundararajan V; Tan DS
    Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
    J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src family kinases maintain the balance between replication stress and the replication checkpoint.
    Miura T; Fukumoto Y; Morii M; Honda T; Yamaguchi N; Nakayama Y; Yamaguchi N
    Cell Biol Int; 2016 Jan; 40(1):16-26. PubMed ID: 26194897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
    Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
    Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.